|Videos|September 24, 2022
Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin
Author(s)Michael Hotchkin
The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]
Advertisement
WATCH TIME: 2 minutes
"It is fascinating how many different neurodegenerative disorders share a commonality of energetic dysfunction. We do have preclinical models suggesting efficacy across a variety of different neurodegenerative diseases: MS, ALS, Alzheimer disease, and multiple other models."
CNM-Au8, an investigational agent consisting of a gold nanocrystal suspension developed by Clene Nanomedicine, poses as a unique candidate in the pipeline for neurological disorders. Currently, the therapeutic is being evaluated in patients with multiple sclerosis (MS) and those with amyotrophic lateral sclerosis (ALS), a neuromuscular disease for which there are only a handful of available treatments.
In August, the company announced positive topline results from its VISIONARY-MS study (NCT03536559), as the agent met both its primary and secondary end points without any significant safety signals found. All told, on Low Contrast Letter Acuity (LCLA) measures—the primary end point—the least squares mean difference was 3.13 (95% CI, –0.08 to 6.33; P = .056) compared with the placebo group in the clinically affected eye over 48 weeks of treatment.1
In the company’s study in ALS, RESCUE-ALS (NCT04098406), despite not meeting its primary or secondary end points in change of Motor Unit Number Index, treatment with the agent resulted in a significant 70% decreased risk of death compared with those initial randomized to placebo.2 Those findings were presented at the 2022 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting , September 21-24, in Nashville, Tennessee.
To learn more about how this candidate successfully treats both neurologic conditions, NeurologyLive® sat down with Michael Hotchkin , chief development officer, Clene Nanomedicine. Hotchkin provided insight on the crossover between these diseases, as well as whether there could be plans to expand CNM-Au8’s range into other disorders.
REFERENCES
1. Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis. News release. Clene Nanomedicine. August 15, 2022. Accessed September 23, 2022. https://www.globenewswire.com/news-release/2022/08/15/2498070/0/en/Clene-Reports-Positive-Topline-Results-for-CNM-Au8-in-the-Phase-2-VISIONARY-MS-Trial-in-Multiple-Sclerosis.html
2. Vucic S, Menon P, Huynh W, et al. Evidence for a Potential Survival Benefit in Amyotrophic Lateral Sclerosis with CNM-Au8 Treatment: Interim Results From the RESCUE-ALS Trial Long-term Open Label Extension. Presented at: AANEM 2022; September 21-24; Nashville, TN. Abstract 206.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Expanding the Alzheimer Drug Development PipelineSeptember 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5
